Please login to the form below

Not currently logged in
Email:
Password:

Sanofi nominates Bonnie Bassler to board

She has over 20 years of experience
Bonnie Bassler

Sanofi has nominated Bonnie Bassler as an independent member of its board of directors.

Bassler serves as a member of the US National Science Board, as appointed by president Barack Obama, which oversees the National Science Foundation.

Her appointment comes shortly after Sanofi's board sacked CEO Christoper Viehbacher.

Commenting on her nomination, Bassler said: “It is a great honour for me to join Sanofi's board of directors. Sanofi is one of the leading international pharmaceutical companies in the world and I look forward to working closely with members on the board and the company to support Sanofi's mission to develop and introduce innovative therapies.”

Bassler has more than 20 years of experience in the sector and is a Howard Hughes Medical Institute investigator, professor in molecular biology and chair of the department of molecular biology at Princeton University, US.

She also serves on oversight, grant, fellowship and award panels for organisations including the National Academies of Sciences and US National Institutes of Health.

Serge Weinberg, chairman of the board and interim CEO at Sanofi, said: “Professor Bassler's scientific expertise in molecular biology and her great leadership skills makes her an outstanding addition to our board.

“We look forward to her contribution to Sanofi's strategy as we continue to innovate and introduce new medicines and vaccines that can help improve health outcomes.”

27th November 2014

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...

Infographics